Anti-CD45RB monoclonal antibody

Drug Profile

Anti-CD45RB monoclonal antibody

Alternative Names: Anti-CD45RB monoclonal antibody MB23G2; Monoclonal antibody MB23G2

Latest Information Update: 16 Apr 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen; University of Groningen; University of Western Ontario
  • Class Monoclonal antibodies
  • Mechanism of Action CD45 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Transplant rejection

Most Recent Events

  • 03 Apr 2006 Abgenix has been acquired and merged into Amgen
  • 28 Jun 2004 This monoclonal antibody is still in active development
  • 19 Jan 1999 Two preclinical studies have been added to the pharmacodynamics section ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top